Future of Medicare drug price negotiations under new administration: 5 things to know

As President-elect Donald Trump prepares to take office, the future of Medicare's drug price negotiation program, part of the 2022 Inflation Reduction Act, is uncertain, Roll Call reported Nov. 15.

The program, which allows the federal government to negotiate prices for high-cost drugs, is a key policy achievement of the Biden administration, but its future could be affected by changes under the new administration and Congress.